SCHEMBL388474

SCHEMBL388474

Cc1c(Oc2ccc(C#N)cn2)ccc2c1CCC2=O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 3/20 0.39
FEN1 P39748 3/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
HSD11B1 P28845 3/20 0.37
HSD11B2 P80365 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
PDE4B Q07343 1/20 0.35
GABRA5 P31644 1/20 0.35
P2RX3 P56373 2/20 0.33
KCNJ1 P48048 2/20 0.33
KCNH2 Q12809 1/20 0.33
OPRM1 P35372 1/20 0.33
CYP11B2 P19099 1/20 0.33
KEAP1 Q14145 1/20 0.33
SCN9A Q15858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6178978 0.83 ALOX5AP (0.44) ALOX5APFEN1HRH3HSD11B1HSD11B2
SCHEMBL388579 0.78 NNMT (0.47) KDM4EALDH1A1HPGDHRH3OPRM1
SCHEMBL3692464 0.69 KEAP1 (0.43) ALOX5APFEN1KDM4EALDH1A1HPGD
SCHEMBL388362 0.68 ALDH1A1 (0.69) KDM4EALDH1A1HPGD
SCHEMBL25168174 0.68 ALDH1A1 (0.42) KDM4EALDH1A1HPGDL3MBTL1
SCHEMBL20155520 0.67 KEAP1 (0.46) ALOX5APFEN1KDM4EALDH1A1L3MBTL1
SCHEMBL3689680 0.67 KDM4E (0.44) ALOX5APFEN1KDM4EALDH1A1L3MBTL1
SCHEMBL385479 0.65 PGR (0.50) HRH3HSD11B1HSD11B2PDE4BP2RX3
SCHEMBL8237112 0.65 KDM4E (0.54) KDM4EALDH1A1HPGDL3MBTL1PDE4B
SCHEMBL2984251 0.64 KEAP1 (0.46) ALOX5APFEN1KDM4EALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101638-B2 6-substituted nicotinamide derivatives as opioid receptor antagonists ELI LILLY AND COMPANY (US) 2012-01-24 US disclosed
US-20090023785-A1 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS PEDREGAL-TERCERO CONCEPCION 2009-01-22 US disclosed
US-7399774-B2 6-substituted nicotinamide derivatives as opioid receptor antagonists ELI LILLY AND COMPANY (US) 2008-07-15 US disclosed
EP-1613597-B1 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2007-11-07 EP disclosed
US-20060205715-A1 6-Substituted nicotinamide derivatives as opioid receptor antagonists ELI LILLY AND COMPANY 2006-09-14 US disclosed
EP-1613597-A1 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS Eli Lilly and Company (US) 2006-01-11 EP disclosed
WO-2004080968-A1 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205715-A1 6-Substituted nicotinamide derivatives as opioid receptor antagonists OPRM1, OPRL1, OPRK1 ALOX5AP 2104/4885FEN1 4673/4885KDM4E 3752/4885
US-20090023785-A1 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS OPRM1, OPRK1, OPRD1 ALOX5AP 2635/4885FEN1 4717/4885KDM4E 4257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.